Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 8Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Neoplasms 3Rectal Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Thrombocythemia, Essential 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Recurrence 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Pathologic Complete Response 1Myelodysplastic-Myeloproliferative Diseases 1Melanoma 1Liver Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Hemangiosarcoma 1Glioma 1Glioblastoma 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 58Dexamethasone 50Rituximab 39Peripheral Blood Stem Cell Transplantation 29Paclitaxel 29Lenalidomide 28fludarabine phosphate 27Gemcitabine 26Etoposide 26Bortezomib 26Cytarabine 25Busulfan 24pembrolizumab 21Radiotherapy 21Bevacizumab 21Carboplatin 20Mycophenolic Acid 19Melphalan 19Cisplatin 19Filgrastim 18pomalidomide 17fludarabine 17Oxaliplatin 17Antilymphocyte Serum 17Cyclosporine 16Tacrolimus 15Methotrexate 15Whole-Body Irradiation 14Methylprednisolone 13Bendamustine Hydrochloride 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Recurrence × veliparib × Clear all
NCT01193140 2012-11-21

To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors

Abbott

Phase 2 Completed
24 enrolled

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡